MCID: HYP069
MIFTS: 59

Hyperparathyroidism

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hyperparathyroidism

MalaCards integrated aliases for Hyperparathyroidism:

Name: Hyperparathyroidism 12 77 30 56 6 45 15 41 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:13543
ICD9CM 36 252.0 252.00
MeSH 45 D006961
NCIt 51 C48259
SNOMED-CT 69 66999008
ICD10 34 E21.3
UMLS 74 C0020502

Summaries for Hyperparathyroidism

Disease Ontology : 12 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body.

MalaCards based summary : Hyperparathyroidism is related to hyperparathyroidism 2 with jaw tumors and hyperparathyroidism 1. An important gene associated with Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs Cinacalcet and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and thyroid, and related phenotypes are cellular and cardiovascular system

Wikipedia : 77 Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. This occurs from a... more...

Related Diseases for Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism
Secondary Hyperparathyroidism

Diseases related to Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 477)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 2 with jaw tumors 34.7 CASR CDC73 MEN1 RET
2 hyperparathyroidism 1 34.6 CDC73 MEN1
3 hyperparathyroidism, neonatal severe 34.5 CASR PRKAR1A
4 familial isolated hyperparathyroidism 34.1 CASR CDC73 GCM2 MEN1 PTH RET
5 osteitis fibrosa 33.2 BGLAP CALCA CASR PTH
6 multiple endocrine neoplasia, type iia 32.5 CALCA CDC73 MEN1 PTH RET
7 parathyroid carcinoma 32.4 CALCA CASR CDC73 MEN1 PTH RET
8 pseudohypoparathyroidism, type ib 32.3 BGLAP PTH PTHLH
9 nephrocalcinosis 32.3 CASR PHEX PTH
10 primary hyperparathyroidism 32.2 ALPP BGLAP CALCA CASR CDC73 CDKN1B
11 multiple endocrine neoplasia, type i 32.1 CASR CDC73 CDKN1B MEN1 PRKAR1A PTH
12 adenoma 31.6 CASR CDC73 MEN1 RET
13 rickets 31.5 BGLAP CYP27B1 FGF23 PHEX PTH VDR
14 vitamin d-dependent rickets, type 2a 31.5 CYP27B1 PHEX VDR
15 parathyroid adenoma 31.5 BGLAP CALCA CASR CDC73 GCM2 MEN1
16 secondary hyperparathyroidism of renal origin 31.4 ACP5 BGLAP CALCA CASR CYP27B1 EPO
17 familial hypocalciuric hypercalcemia 31.2 CASR CDC73 PTH
18 parathyroid gland disease 31.2 BGLAP CALCA CASR CDC73 FGF23 GCM2
19 hypocalciuric hypercalcemia, familial, type i 30.9 CASR PTH
20 nephrolithiasis 30.9 CASR FGF23 PTH VDR
21 multiple endocrine neoplasia 30.8 CALCA CDKN1B MEN1 PRKAR1A RET
22 kidney disease 30.6 CASR EPO FGF23 PTH TNFRSF11B VDR
23 uremia 30.5 CASR EPO PTH TNFRSF11B VDR
24 paget's disease of bone 30.5 BGLAP CALCA TNFRSF11B
25 calciphylaxis 30.5 CASR EPO FGF23 PTH VDR
26 pseudohypoparathyroidism 30.5 BGLAP PTH PTHLH
27 fibrous dysplasia 30.5 BGLAP CALCA FGF23
28 calcinosis 30.4 CALCA FGF23 PHEX
29 giant cell tumor 30.4 BGLAP CALCA TNFRSF11B
30 bone inflammation disease 30.4 ACP5 BGLAP TNFRSF11B
31 idiopathic hypercalciuria 30.3 BGLAP CASR PRKAR1A VDR
32 clear cell adenoma 30.3 MEN1 PTH PTHLH
33 thyroid carcinoma, familial medullary 30.3 CALCA MEN1 RET
34 osteomalacia 30.2 BGLAP CALCA CASR FGF23 PHEX PTH
35 hypophosphatemic rickets, x-linked recessive 30.1 CYP27B1 FGF23 PHEX VDR
36 renal osteodystrophy 30.1 BGLAP CALCA CASR FGF23 PTH TNFRSF11B
37 parathyroid transitional clear cell adenoma 30.1 MEN1 PTH
38 hypophosphatemia 30.1 BGLAP FGF23 PHEX PTH
39 differentiated thyroid carcinoma 30.0 BGLAP RET TNFRSF11B
40 hypoparathyroidism 30.0 ALPP BGLAP CASR FGF23 GCM2 PTH
41 chief cell adenoma 30.0 GCM2 PTH
42 hyperphosphatemia 30.0 CASR FGF23 GCM2 PHEX PTH VDR
43 follicular adenoma 30.0 CALCA CDKN1B RET
44 multiple endocrine neoplasia, type iv 29.9 CDKN1B MEN1 PRKAR1A RET
45 hashimoto thyroiditis 29.9 CALCA CYP27B1 RET
46 invasive malignant thymoma 29.8 PTH PTHLH
47 hypophosphatemic rickets, x-linked dominant 29.8 FGF23 PHEX PTH
48 oncogenic osteomalacia 29.7 FGF23 PHEX PTH PTHLH
49 chronic kidney failure 29.7 BGLAP CALCA CASR CYP27B1 EPO FGF23
50 islet cell tumor 29.7 CALCA MEN1 PTHLH

Comorbidity relations with Hyperparathyroidism via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Hypertension, Essential
Hypoparathyroidism Hypothyroidism
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Parathyroid Carcinoma

Graphical network of the top 20 diseases related to Hyperparathyroidism:



Diseases related to Hyperparathyroidism

Symptoms & Phenotypes for Hyperparathyroidism

MGI Mouse Phenotypes related to Hyperparathyroidism:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 CASR CDC73 CDKN1B CYP27B1 EPO GCM2
2 cardiovascular system MP:0005385 10.36 CDC73 CDKN1B EPO FGF23 MEN1 PHEX
3 endocrine/exocrine gland MP:0005379 10.36 CASR CDC73 CDKN1B CYP27B1 FGF23 GCM2
4 homeostasis/metabolism MP:0005376 10.36 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
5 growth/size/body region MP:0005378 10.35 CASR CDC73 CDKN1B CYP27B1 FGF23 MEN1
6 hematopoietic system MP:0005397 10.34 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
7 immune system MP:0005387 10.34 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
8 craniofacial MP:0005382 10.31 CDC73 CDKN1B CYP27B1 GCM2 MEN1 PHEX
9 digestive/alimentary MP:0005381 10.26 CASR CDC73 CDKN1B FGF23 MEN1 PHEX
10 mortality/aging MP:0010768 10.25 CASR CDC73 CDKN1B EPO FGF23 GCM2
11 integument MP:0010771 10.13 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
12 limbs/digits/tail MP:0005371 10.11 CYP27B1 EPO FGF23 PHEX PTH PTHLH
13 adipose tissue MP:0005375 10.07 CDC73 CDKN1B CYP27B1 PHEX PRKAR1A PTHLH
14 liver/biliary system MP:0005370 9.98 CDC73 CDKN1B EPO MEN1 PHEX PRKAR1A
15 muscle MP:0005369 9.97 CASR CDC73 CDKN1B EPO MEN1 PRKAR1A
16 renal/urinary system MP:0005367 9.96 CASR CDC73 CDKN1B CYP27B1 FGF23 GCM2
17 reproductive system MP:0005389 9.81 CDC73 CDKN1B CYP27B1 FGF23 MEN1 PRKAR1A
18 neoplasm MP:0002006 9.8 CDC73 CDKN1B MEN1 PRKAR1A PTHLH RET
19 respiratory system MP:0005388 9.5 CDC73 CDKN1B EPO FGF23 PRKAR1A PTHLH
20 skeleton MP:0005390 9.44 CASR CDC73 CDKN1B CYP27B1 EPO FGF23

Drugs & Therapeutics for Hyperparathyroidism

Drugs for Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cinacalcet Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 226256-56-0 156419
2
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
4
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9002-64-6
5
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
6
Calcium acetate Approved, Investigational Phase 4,Phase 3,Not Applicable 62-54-4
7
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
8
Alendronate Approved Phase 4,Phase 2,Not Applicable 66376-36-1, 121268-17-5 2088
9
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
10
Ethanol Approved Phase 4 64-17-5 702
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Angiotensin II Approved, Investigational Phase 4,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
15
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
16
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
17
Zoledronic Acid Approved Phase 4,Phase 1 118072-93-8 68740
18
Pamidronate Approved Phase 4 40391-99-9 4674
19 Menaquinone Approved, Investigational Phase 4 1182-68-9
20
Phylloquinone Approved, Investigational Phase 4 84-80-0
21
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
22
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1406-16-2
24
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
25
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-14-6 5280793
26
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 67-97-0 5280795 6221
27
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 32222-06-3 5280453 134070
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
29
Calcifediol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19356-17-3 5283731 6433735
30
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 41294-56-8 5282181
31
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Vitamin D2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Calciferol Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 retinol Phase 4

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Intravenous Paricalcitol in Chronic Hemodialysis Patients Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
3 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
4 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
5 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
6 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
7 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
8 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
9 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
10 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
11 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
12 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
13 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
14 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4 cinacalcet;cinacalcet dose 1;cinacalcet dose 2
15 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
16 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
17 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
18 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
19 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
20 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
21 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4 10,000 IU Vitamin D3
22 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
23 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Completed NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
24 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
25 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
26 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
27 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
28 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
29 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
30 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
31 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
32 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
33 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
34 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
35 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
36 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
37 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
38 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
39 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
40 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
41 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
42 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
43 Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients Completed NCT03648528 Phase 4 cholecalciferol;placebo
44 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
45 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
46 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
47 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
48 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Completed NCT02572960 Phase 4 Valsartan;Placebo Valsartan
49 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
50 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3

Search NIH Clinical Center for Hyperparathyroidism

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperparathyroidism

Genetic Tests for Hyperparathyroidism

Genetic tests related to Hyperparathyroidism:

# Genetic test Affiliating Genes
1 Hyperparathyroidism 30

Anatomical Context for Hyperparathyroidism

MalaCards organs/tissues related to Hyperparathyroidism:

42
Bone, Kidney, Thyroid, Testes, Heart, Breast, Endothelial

Publications for Hyperparathyroidism

Articles related to Hyperparathyroidism:

(show top 50) (show all 6409)
# Title Authors Year
1
Primary hyperparathyroidism due to ectopic parathyroid adenoma in an adolescent: a case report and review of the literature. ( 30805889 )
2019
2
Importance of Parathyroid Hormone Needle Aspiration Washout in Adenoma Localization in Primary Hyperparathyroidism. ( 30834899 )
2019
3
A Case of Pregnancy Complicated by Primary Hyperparathyroidism Due to a Parathyroid Adenoma. ( 30636767 )
2019
4
Management of Post-transplant Hyperparathyroidism and Bone Disease. ( 30811012 )
2019
5
Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism. ( 30641521 )
2019
6
New Concepts About Familial Isolated Hyperparathyroidism. ( 30848815 )
2019
7
The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. ( 31014177 )
2019
8
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. ( 31015494 )
2019
9
A Comparison between Silent and Symptomatic Renal Stones in Primary Hyperparathyroidism. ( 31016152 )
2019
10
Postsurgical Evaluation of Secondary Nephrogenic Hyperparathyroidism. ( 31016519 )
2019
11
Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia: Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral. ( 31019019 )
2019
12
Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism. ( 31022778 )
2019
13
Two cases of spontaneous remission of primary hyperparathyroidism due to auto-infarction: different management and their outcomes. ( 31063971 )
2019
14
Seventeen Cases of Primary Hyperparathyroidism in Pregnancy: A Call for Management Guidelines. ( 31065618 )
2019
15
Cervical re-explorations and proxy survival following parathyroidectomy for primary hyperparathyroidism using Australian administrative data. ( 31067607 )
2019
16
Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. ( 31068134 )
2019
17
Plasma metabolite biomarkers related to secondary hyperparathyroidism and parathyroid hormone. ( 31069832 )
2019
18
Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range. ( 31074404 )
2019
19
Fahr's syndrome with hyperparathyroidism revealed by seizures and proximal weakness. ( 31080899 )
2019
20
Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. ( 31092749 )
2019
21
Bilateral Forearm Fractures During Modified Electroconvulsive Therapy in a Male Patient With a History of Hyperparathyroidism and Elevated Pseudocholinesterase Activity. ( 31094876 )
2019
22
Management of primary hyperparathyroidism in pregnancy: a case series. ( 31096181 )
2019
23
Surgical Treatment of Hyperparathyroidism After Kidney Transplant. ( 31101206 )
2019
24
Parathyroid scintigraphy in primary hyperparathyroidism: comparison between double-phase and subtraction techniques and possible affecting factors. ( 30600433 )
2019
25
Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. ( 30608029 )
2019
26
Synchronous primary hyperparathyroidism, follicular thyroid carcinoma, and papillary thyroid carcinoma. ( 30614854 )
2019
27
Bone mineral density evolution and incidence of fractures in a cohort of patients with primary hyperparathyroidism treated with parathyroid surgery vs active surveillance during 6 years of follow-up. ( 30616776 )
2019
28
Primary Hyperparathyroidism. ( 30641515 )
2019
29
Secondary and Tertiary Hyperparathyroidism. ( 30641516 )
2019
30
Familial and Hereditary Forms of Primary Hyperparathyroidism. ( 30641519 )
2019
31
Asymptomatic Primary Hyperparathyroidism. ( 30641522 )
2019
32
Normocalcemic Hyperparathyroidism. ( 30641527 )
2019
33
Perioperative hyperkalemia in hemodialysis patients undergoing parathyroidectomy for renal hyperparathyroidism. ( 30648222 )
2019
34
A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism. ( 30651833 )
2019
35
The role of ultrasound in the diagnosis of the coexistence of primary hyperparathyroidism and non-medullary thyroid carcinoma. ( 30658569 )
2019
36
18F-Fluorocholine PET/CT and Parathyroid 4D Computed Tomography for Primary Hyperparathyroidism: The Challenge of Reoperative Patients. ( 30659347 )
2019
37
Medication Prescription Patterns for Secondary Hyperparathyroidism: More Questions than Answers. ( 30665921 )
2019
38
Perioperative characteristics, histological diagnosis, and outcome in cats undergoing surgical treatment of primary hyperparathyroidism. ( 30666680 )
2019
39
Intraoperative Parathyroid Autofluorescence Detection in Patients with Primary Hyperparathyroidism. ( 30675703 )
2019
40
US-guided microwave ablation for secondary hyperparathyroidism in patients after renal transplantation: a pilot study. ( 30676132 )
2019
41
Bilateral Neck Exploration for Sporadic Primary Hyperparathyroidism: Use Patterns in 5,597 Patients Undergoing Parathyroidectomy in the Collaborative Endocrine Surgery Quality Improvement Program. ( 30677525 )
2019
42
Does Primary Hyperparathyroidism Have an Association with Thyroid Papillary Cancer? A Retrospective Cohort Study. ( 30680499 )
2019
43
The role of combined techniques of scintigraphy and SPECT/CT in the diagnosis of primary hyperparathyroidism: A case report. ( 30681579 )
2019
44
Peritoneal dialysis can alleviate the clinical course of hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 30689179 )
2019
45
Parathyroid-targeted overexpression of Regulator of G-Protein Signaling 5 (R GS5) causes hyperparathyroidism in transgenic mice. ( 30690792 )
2019
46
Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report. ( 30691427 )
2019
47
Potential Utility of Contrast-Enhanced Ultrasound in the Preoperative Evaluation of Primary Hyperparathyroidism. ( 30693978 )
2019
48
Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. ( 30699421 )
2019
49
Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas. ( 30706095 )
2019
50
Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism. ( 30712039 )
2019

Variations for Hyperparathyroidism

ClinVar genetic disease variations for Hyperparathyroidism:

6 (show top 50) (show all 68)
# Gene Variation Type Significance SNP ID Assembly Location
1 MEN1 NM_130799.2(MEN1): c.1296G> A (p.Leu432=) single nucleotide variant Conflicting interpretations of pathogenicity rs138770431 GRCh37 Chromosome 11, 64572560: 64572560
2 MEN1 NM_130799.2(MEN1): c.1296G> A (p.Leu432=) single nucleotide variant Conflicting interpretations of pathogenicity rs138770431 GRCh38 Chromosome 11, 64805088: 64805088
3 MEN1 NM_130799.2(MEN1): c.774G> C (p.Gln258His) single nucleotide variant Uncertain significance rs374659656 GRCh37 Chromosome 11, 64575033: 64575033
4 MEN1 NM_130799.2(MEN1): c.774G> C (p.Gln258His) single nucleotide variant Uncertain significance rs374659656 GRCh38 Chromosome 11, 64807561: 64807561
5 MEN1 NM_000244.3(MEN1): c.1269C> T (p.Asp423=) single nucleotide variant Benign/Likely benign rs2071313 GRCh37 Chromosome 11, 64572602: 64572602
6 MEN1 NM_000244.3(MEN1): c.1269C> T (p.Asp423=) single nucleotide variant Benign/Likely benign rs2071313 GRCh38 Chromosome 11, 64805130: 64805130
7 MEN1 NM_130799.2(MEN1): c.435C> T (p.Ser145=) single nucleotide variant Benign/Likely benign rs61736636 GRCh37 Chromosome 11, 64577147: 64577147
8 MEN1 NM_130799.2(MEN1): c.435C> T (p.Ser145=) single nucleotide variant Benign/Likely benign rs61736636 GRCh38 Chromosome 11, 64809675: 64809675
9 MEN1 NM_000244.3(MEN1): c.578C> T (p.Pro193Leu) single nucleotide variant Uncertain significance rs199706698 GRCh37 Chromosome 11, 64575454: 64575454
10 MEN1 NM_000244.3(MEN1): c.578C> T (p.Pro193Leu) single nucleotide variant Uncertain significance rs199706698 GRCh38 Chromosome 11, 64807982: 64807982
11 MEN1 NM_000244.3(MEN1): c.526C> T (p.Arg176Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs143329068 GRCh37 Chromosome 11, 64575506: 64575506
12 MEN1 NM_000244.3(MEN1): c.526C> T (p.Arg176Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs143329068 GRCh38 Chromosome 11, 64808034: 64808034
13 MEN1 NM_130799.2(MEN1): c.1535C> T (p.Ser512Leu) single nucleotide variant Uncertain significance rs141679530 GRCh38 Chromosome 11, 64804632: 64804632
14 MEN1 NM_130799.2(MEN1): c.1535C> T (p.Ser512Leu) single nucleotide variant Uncertain significance rs141679530 GRCh37 Chromosome 11, 64572104: 64572104
15 MEN1 NM_130799.2(MEN1): c.1764G> A (p.Lys588=) single nucleotide variant Conflicting interpretations of pathogenicity rs373669288 GRCh38 Chromosome 11, 64804403: 64804403
16 MEN1 NM_130799.2(MEN1): c.1764G> A (p.Lys588=) single nucleotide variant Conflicting interpretations of pathogenicity rs373669288 GRCh37 Chromosome 11, 64571875: 64571875
17 MEN1 NM_130799.2(MEN1): c.*557C> A single nucleotide variant Uncertain significance rs886048471 GRCh38 Chromosome 11, 64803777: 64803777
18 MEN1 NM_130799.2(MEN1): c.*557C> A single nucleotide variant Uncertain significance rs886048471 GRCh37 Chromosome 11, 64571249: 64571249
19 MEN1 NM_130799.2(MEN1): c.*529A> G single nucleotide variant Uncertain significance rs886048472 GRCh38 Chromosome 11, 64803805: 64803805
20 MEN1 NM_130799.2(MEN1): c.*529A> G single nucleotide variant Uncertain significance rs886048472 GRCh37 Chromosome 11, 64571277: 64571277
21 MEN1 NM_130799.2(MEN1): c.*527G> T single nucleotide variant Uncertain significance rs886048473 GRCh37 Chromosome 11, 64571279: 64571279
22 MEN1 NM_130799.2(MEN1): c.*527G> T single nucleotide variant Uncertain significance rs886048473 GRCh38 Chromosome 11, 64803807: 64803807
23 MEN1 NM_130799.2(MEN1): c.*392G> A single nucleotide variant Uncertain significance rs886048475 GRCh37 Chromosome 11, 64571414: 64571414
24 MEN1 NM_130799.2(MEN1): c.*392G> A single nucleotide variant Uncertain significance rs886048475 GRCh38 Chromosome 11, 64803942: 64803942
25 MEN1 NM_130799.2(MEN1): c.*302C> T single nucleotide variant Likely benign rs1804849 GRCh37 Chromosome 11, 64571504: 64571504
26 MEN1 NM_130799.2(MEN1): c.*302C> T single nucleotide variant Likely benign rs1804849 GRCh38 Chromosome 11, 64804032: 64804032
27 MEN1 NM_130799.2(MEN1): c.*272T> C single nucleotide variant Uncertain significance rs563783609 GRCh37 Chromosome 11, 64571534: 64571534
28 MEN1 NM_130799.2(MEN1): c.*272T> C single nucleotide variant Uncertain significance rs563783609 GRCh38 Chromosome 11, 64804062: 64804062
29 MEN1 NM_130799.2(MEN1): c.*185C> T single nucleotide variant Likely benign rs111895237 GRCh37 Chromosome 11, 64571621: 64571621
30 MEN1 NM_130799.2(MEN1): c.*185C> T single nucleotide variant Likely benign rs111895237 GRCh38 Chromosome 11, 64804149: 64804149
31 MEN1 NM_130799.2(MEN1): c.*89G> A single nucleotide variant Uncertain significance rs886048478 GRCh37 Chromosome 11, 64571717: 64571717
32 MEN1 NM_130799.2(MEN1): c.*89G> A single nucleotide variant Uncertain significance rs886048478 GRCh38 Chromosome 11, 64804245: 64804245
33 MEN1 NM_130799.2(MEN1): c.-23-14G> C single nucleotide variant Uncertain significance rs886048479 GRCh37 Chromosome 11, 64577618: 64577618
34 MEN1 NM_130799.2(MEN1): c.-23-14G> C single nucleotide variant Uncertain significance rs886048479 GRCh38 Chromosome 11, 64810146: 64810146
35 MEN1 NM_130799.2(MEN1): c.*560G> T single nucleotide variant Uncertain significance rs886048470 GRCh38 Chromosome 11, 64803774: 64803774
36 MEN1 NM_130799.2(MEN1): c.*560G> T single nucleotide variant Uncertain significance rs886048470 GRCh37 Chromosome 11, 64571246: 64571246
37 MEN1 NM_130799.2(MEN1): c.*470A> G single nucleotide variant Conflicting interpretations of pathogenicity rs778272737 GRCh37 Chromosome 11, 64571336: 64571336
38 MEN1 NM_130799.2(MEN1): c.*470A> G single nucleotide variant Conflicting interpretations of pathogenicity rs778272737 GRCh38 Chromosome 11, 64803864: 64803864
39 MEN1 NM_130799.2(MEN1): c.-35A> T single nucleotide variant Benign/Likely benign rs679946 GRCh37 Chromosome 11, 64578113: 64578113
40 MEN1 NM_130799.2(MEN1): c.-35A> T single nucleotide variant Benign/Likely benign rs679946 GRCh38 Chromosome 11, 64810641: 64810641
41 MEN1 NM_130799.2(MEN1): c.*794G> A single nucleotide variant Uncertain significance rs117705251 GRCh38 Chromosome 11, 64803540: 64803540
42 MEN1 NM_130799.2(MEN1): c.*794G> A single nucleotide variant Uncertain significance rs117705251 GRCh37 Chromosome 11, 64571012: 64571012
43 MEN1 NM_130799.2(MEN1): c.*570C> A single nucleotide variant Uncertain significance rs886048469 GRCh38 Chromosome 11, 64803764: 64803764
44 MEN1 NM_130799.2(MEN1): c.*570C> A single nucleotide variant Uncertain significance rs886048469 GRCh37 Chromosome 11, 64571236: 64571236
45 MEN1 NM_130799.2(MEN1): c.*533C> T single nucleotide variant Uncertain significance rs879327862 GRCh38 Chromosome 11, 64803801: 64803801
46 MEN1 NM_130799.2(MEN1): c.*533C> T single nucleotide variant Uncertain significance rs879327862 GRCh37 Chromosome 11, 64571273: 64571273
47 MEN1 NM_130799.2(MEN1): c.*307T> G single nucleotide variant Likely benign rs1804848 GRCh37 Chromosome 11, 64571499: 64571499
48 MEN1 NM_130799.2(MEN1): c.*307T> G single nucleotide variant Likely benign rs1804848 GRCh38 Chromosome 11, 64804027: 64804027
49 MEN1 NM_130799.2(MEN1): c.327A> C (p.Glu109Asp) single nucleotide variant Uncertain significance rs773976527 GRCh37 Chromosome 11, 64577255: 64577255
50 MEN1 NM_130799.2(MEN1): c.327A> C (p.Glu109Asp) single nucleotide variant Uncertain significance rs773976527 GRCh38 Chromosome 11, 64809783: 64809783

Expression for Hyperparathyroidism

Search GEO for disease gene expression data for Hyperparathyroidism.

Pathways for Hyperparathyroidism

GO Terms for Hyperparathyroidism

Biological processes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 BGLAP CDKN1B PTH RET TNFRSF11B
2 negative regulation of cell proliferation GO:0008285 9.97 CDC73 CDKN1B CYP27B1 MEN1 PTHLH VDR
3 cell-cell signaling GO:0007267 9.92 CALCA PHEX PTH PTHLH
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.82 CALCA PTH PTHLH
5 ossification GO:0001503 9.81 ACP5 BGLAP CASR
6 negative regulation of epithelial cell proliferation GO:0050680 9.77 CDC73 CDKN1B MEN1
7 response to estrogen GO:0043627 9.73 BGLAP CYP27B1 EPO TNFRSF11B
8 decidualization GO:0046697 9.69 CYP27B1 MEN1 VDR
9 cellular calcium ion homeostasis GO:0006874 9.67 CASR GCM2 PTH VDR
10 negative regulation of chondrocyte differentiation GO:0032331 9.65 PTH PTHLH
11 regulation of bone mineralization GO:0030500 9.65 BGLAP CYP27B1 FGF23
12 positive regulation of keratinocyte differentiation GO:0045618 9.64 CYP27B1 VDR
13 negative regulation of bone resorption GO:0045779 9.63 CALCA TNFRSF11B
14 response to inorganic substance GO:0010035 9.63 BGLAP TNFRSF11B
15 osteoblast development GO:0002076 9.63 BGLAP MEN1 PTHLH
16 skeletal system development GO:0001501 9.63 BGLAP PHEX PTH PTHLH TNFRSF11B VDR
17 response to magnesium ion GO:0032026 9.62 FGF23 TNFRSF11B
18 cellular response to parathyroid hormone stimulus GO:0071374 9.61 FGF23 PHEX
19 cellular phosphate ion homeostasis GO:0030643 9.61 FGF23 GCM2
20 phosphate ion homeostasis GO:0055062 9.59 FGF23 PTH
21 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
22 negative regulation of calcium ion transport into cytosol GO:0010523 9.58 CALCA EPO
23 vitamin D metabolic process GO:0042359 9.58 CYP27B1 FGF23 VDR
24 cAMP metabolic process GO:0046058 9.56 PTH PTHLH
25 response to vitamin D GO:0033280 9.56 BGLAP CYP27B1 PHEX PTH
26 response to sodium phosphate GO:1904383 9.55 FGF23 PHEX
27 vitamin D catabolic process GO:0042369 9.54 CYP27B1 FGF23
28 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.5 CYP27B1 FGF23 VDR
29 response to pain GO:0048265 9.36 RET
30 vasodilation GO:0042311 9.35 CASR
31 cellular response to vitamin D GO:0071305 9.26 BGLAP CASR FGF23 PHEX
32 bone mineralization GO:0030282 8.92 BGLAP CYP27B1 PHEX PTHLH
33 regulation of signaling receptor activity GO:0010469 10 CALCA EPO FGF23 PTH PTHLH TNFRSF11B

Molecular functions related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 8.96 PTH PTHLH
2 hormone activity GO:0005179 8.92 CALCA EPO PTH PTHLH

Sources for Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....